Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.

Executive Summary

Alza drug delivery technologies reduce the cost of developing an enhanced version of an already-marketed drug to $70 mil.-$80 mil., Alza Chairman Sam Saks, MD, said during Johnson & Johnson's business review Sept. 23
Advertisement

Related Content

Lilly cashes out on dapoxetine
Lilly cashes out on dapoxetine
Tufts R&D Cost Estimate Puts Cash Outlay At $403 Mil. Per NCE
J&J's Revamped R&D Will Release First Drug In 2004, Diabetic Likely Choice
J&J Risperdal, Topamax Are Candidates For Alza Drug Delivery Systems
J&J Risperdal, Topamax Are Candidates For Alza Drug Delivery Systems
Advertisement
UsernamePublicRestriction

Register

PS040527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel